Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

NENT Group to stream Wilder vs. Fury boxing world title rematch

· Viaplay to show exclusive coverage across the Nordic region of WBC world title fight on 22 February · Wilder vs. Fury rematch is one of the year’s most anticipated boxing events · NENT Group shows more than 50,000 hours of the world’s best live sporting action every year Nordic Entertainment Group (NENT Group), the Nordic region’s leading streaming company, will show pan-Nordic exclusive coverage of the boxing world title fight between Deontay Wilder and Tyson Fury in Las Vegas on 22 February. The two heavyweights delivered an all-time classic bout in 2018 that ended in a split

Invitation to presentation of Nordic Waterproofing’s fourth quarter 2019 report

Nordic Waterproofing Holding A/S will publish its interim report for January-December 2019 on Thursday, 6 February 2020, at approximately 08:00 a.m. CET. A conference call and web presentation for investors, analysts and media will be held the same day, at 10:00 a.m. CET.The CEO, Mr. Martin Ellis, and the CFO, Mr. Jonas Olin, will present and comment the report as well as answer questions following the presentation. The presentation will be held in English via a telephone conference and a live webcast will be available on www.nordicwaterproofing.com 

Nightingale’s advanced blood-testing for consumers begins service in Helsinki

The new consumer service, My Nightingale blood test and app, delivers advanced blood analysis results that predict chronic disease risk and help people prevent them by making lifestyle changes. As a part of the end-to-end consumer experience, the company also opened Nightingale Nest, its first blood-drawing location in Helsinki.Finland’s Nightingale Health, an innovator in blood-testing technology, today welcomed the first customers of My Nightingale in Helsinki. My Nightingale is an advanced blood-testing service for individuals, which predicts the risk of chronic diseases up to 10 years

Clinical data for Episealer® to be presented at orthopaedic congress in The United Kingdom

Episurf Medical (Nasdaq: EPIS B) today announces that the company’s knee implant technology and clinical results will be presented at the 6th Annual Meeting of the UK Biological Knee Society, on January 30-31 in Cambridge, the United Kingdom. M.D. Ph.D. M. Högström at Sports Medicine Umeå, Sweden, has been invited to the meeting to give the presentation “Metal Mini Prosthesis for Focal Chondral Lesions”. The presentation is based on the clinical results from a European multicenter study with 100 patients in the “gap age”, 35-60 years old, that have undergone treatment of focal chondral

Contract award for Skandi Vitoria

The Brazilian built pipelay support vessel (PLSV) Skandi Vitoria, owned by the joint venture between DOF Subsea (50%) and TechnipFMC (50%), has been awarded a contract with TechnipFMC. The contract will commence in January with validity of two years plus options. The vessel has been in lay-up since summer 2018 and the CEO Mons Aase states that he is pleased with the contract award and having the vessel back in operations. For further information, please contact: Mons S. Aase, CEO Tel: +47 91 66 10 12 Hilde Drønen, CFO Tel: 91 66 10 09

Transparency Germany welcomes corruption investigation into Karin Strenz and Eduard Lintner

The anti-corruption organisation Transparency Deutschland welcomes the investigation by the public prosecutor's office in Frankfurt am Main into corruption allegations against Karin Strenz and Eduard Lintner. In March 2019, Transparency Germany filed criminal complaints  against these current and former members of Bundestag for bribery and corruption of public officials in the course of the Azerbaijani Laundromat scandal 

Atea announces cost efficiency program and change of Managing Director in Atea Denmark

Atea Denmark had improved profitability in the fourth quarter of 2019, but the business recovery has taken longer and been slower than management’s expectations. The Atea Denmark business segment will report an EBIT of DKK 17 million in Q4 2019, compared with DKK 8 million last year. Consequently, Atea Denmark is undertaking a cost efficiency program which involves the reduction of 67 full time employees, effective from January 2020. The program will result in severance costs of DKK 26 million, which will be recognized as a restructuring charge during the first quarter of 2020. In

AAK’s Interim report for the fourth quarter and year-end report 2019 – continued profit growth and new strategic direction

AAK Group, fourth quarter · Total volumes for the quarter amounted to 582,000 MT (574,000), organic growth of 1 percent (4). · Sales amounted to SEK 7,380 million (6,992), an increase of 6 percent. · Operating profit, including a positive currency translation impact of SEK 12 million, reached SEK 562 million (516), an improvement of 9 percent. Operating profit per kilo improved by 8 percent to SEK 0.97 (0.90). · Net result amounted to SEK 401 million (354), an improvement of 13 percent. · Earnings per share increased by 12 percent, to SEK 1.56 (1.39). · Cash

Mandatory Notification of Trade

Ousdal AS, a company wholly owned by Riulf Rustad, chairman of the board of Norwegian Energy Company ASA (“Noreco”), has on 29 January 2020 acquired options to buy up to 400,000 shares in Noreco with a strike price of NOK 315 for a consideration of NOK 11 per option, valid until 30 November 2021. In connection with this transaction, Ousdal AS has sold 66,000 shares at a price of NOK 224 per share. Following these transactions, Riulf Rustad, and companies controlled by him, will own 146,975 shares and 890,000 options to buy or subscribe for shares in Noreco, in total 1,036,975 shares and

Gene expression analysis method has been validated by a commercial laboratory

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that the method  for gene expression analysis has been validated by a commercial laboratory, a request from regulatory authorities for use in clinical practice.Academic data from approximately 450 patients, all treated with 5-FU and leucovorin containing regimens, has demonstrated a difference in PFS with patients having a high expression of certain folate relevant genes versus those who have lower expression levels. “With the validated gene expression analysis method,

UPM Financial Statements Release 2019: UPM reports good performance and record cash flow – Uruguay investment drives significant future earnings growth

UPM-Kymmene Corporation      Financial Statements Release 2019          30 January 2020 at 9:40 EET UPM Financial Statements Release 2019:UPM reports good performance and record cash flow – Uruguay investment drives significant future earnings growth Q4 2019 highlights · Sales decreased by 10% to EUR 2,447 million (2,731 million in Q4 2018) due to lower pulp price and lower deliveries of graphic papers · Comparable EBIT decreased by 15% to EUR 343 million (404 million) · Record quarterly operating cash flow at EUR 592 million (384 million) · Net debt decreased to EUR -

Follicum's Phase II study with FOL-005 for treatment of Alopecia approved by the German Medicines Agency

Follicum AB ("Follicum" or "the Company") today announces that it has received approval from the German Medicines Agency (BfArM) and the German Ethics Committee to start a Phase IIa clinical study with a topical formulation of FOL-005 on patients with alopecia (hair loss). The trial will comprise about 200 patients who will be treated with FOL-005 or placebo daily for 4 months. The study is conducted in collaboration with the Charité Clinical Research Center for Hair and Skin Science ("CRC") in Berlin and proDERM, Hamburg, Germany.In two previous clinical studies, FOL-005 has been shown to

Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test

2cureX AB (“2cureX”, NASDAQ: 2CUREX) is pleased to announce that 35 patients have been treated in accordance with the IndiTreat test in our colorectal cancer trial (ClinicalTrials.gov Identifier: NCT03251612). We are thus on track and expect that all the planned 45 patients are treated by Q3, 2020.The clinical trial was initiated by Vejle University Hospital, selected by “Dagens Medicin” as the best cancer hospital in Denmark for four consecutive year Lars Henrik Jensen, Chief Oncologist and Chairman of Interdisciplinary Oncology Committee of the Danish Medicines Council, is the

Over 200 patients now randomized in the Global Phase 3 AGENT Study

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced that over 200 patients of the planned 440 has been randomized in the global Phase 3 AGENT Study. The study has over 80 clinical sites in the U.S., Canada, Europe, Australia and Japan. The target of 330 patients randomized for the interim analysis is expected to be achieved in the second quarter of 2020.Over 200 patients are now randomized in the Phase 3 AGENT Study, a registration clinical trial of arfolitixorin in first-line metastatic colorectal cancer (mCRC) patients. The

Medivir has received notices of allowance in the EU and Japan for MIV-818 patent applications

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports that the MIV-818 patent portfolio has been reinforced by the issue of notices of allowance from the European Patent Office and the Japanese Patent Office for the MIV-818 composition-of-matter and liver cancer treatment claims. Corresponding notices of allowance or patent grants have already been issued in USA, Australia, Indonesia, Israel, Philippines, Russia, Singapore and South Africa. Applications are pending in a large number of other countries in Asia and around the world. The patents will be in force until August 2035.

Klaria Pharma presents new strategy, upcoming milestones and new website

Today, Klaria Pharma Holding AB (publ) (”Klaria”) announces that it has formulated and is now implementing a new strategy. Klaria will focus all research and development exclusively on programs where Klaria’s films have the potential to replace injections or nasal sprays, and where formulations constitute a major problem for patients, caregivers or payers. Since Klaria’s Alginate Film technology has significant advantages to both injections and nasal sprays, this strategy ensures that resources are focused on programs where the unmet medical needs are significant and where development of oral

Year End Report 2019

Press release, Stockholm, Sweden, 30 January 2020 TagMaster’s profitable growth continues – the best result to date Fourth quarter · Net sales increased during the fourth quarter by 89,6% to 83,5 MSEK (44,1) · Adjusted EBITDA amounted to 8,7 MSEK (0,9), corresponding to a margin of 10,4% (2,0) · EBITDA for the fourth quarter amounted to 4,3 MSEK (0,9), corresponding to a margin of 5,2% (2,0) · Net result after tax was -9,4 MSEK (-0,5) whereof amortizations of goodwill in accordance with the standard accounting principles (K3) applied by TagMaster amounted to -9,7 MSEK

Baccarat added to Evolution’s award-winning Lightning range

Evolution Gaming, leading provider of Live Casino solutions, has added to its award-winning Lightning range with the launch of an exclusive, all-new game, Lightning Baccarat.This new Lightning game, which again combines live play with high-payout RNG multipliers, is part of Evolution’s line-up of new releases for ICE 2020 and is an exciting new take on classic Baccarat. As in standard Live Baccarat, players try to predict whose hand, Player or Banker, will win by having the value closest to 9. Unlike traditional Baccarat, however, after betting time has expired a Lightning Round begins

Evolution selected by Groupe Partouche for launch in the Swiss market

Evolution Gaming, leading provider of Live Casino solutions, announced today that it has been selected by Groupe Partouche to deliver online Live Casino services to the regulated Swiss market.Partouche’s Evolution-powered Live Casino — scheduled for launch during the first half of 2020 — will allow the group’s customers in Switzerland to play a rich mix of online live games on smartphones, tablet and desktop. The live games from Evolution’s wide-ranging, award-winning portfolio will include live dealer Roulette, Baccarat, numerous live dealer Poker variants, as well as games such as

Wallenstam invests in co-living in Kallebäcks Terrasser

Wallenstam and Colive have signed an agreement on developing co-living housing, a so-called “co-living hub” in Kallebäcks Terrasser, one of Gothenburg’s largest urban development areas. The agreement relates to co-living apartments for 117 tenants, divided between a seven-floor building and a five-floor building with expected occupation during fall 2022. Kallebäcks Terrasser in the longer term will consist of 1,800 new homes and 1,200 office workspaces as well as schools, nursery schools, restaurants, cafés and local services.“We already have a project together with Colive in Haninge and we

Beijer Ref AB Q4-2019

Increased profits, acquisition and increased dividendFourth quarter Net sales increased by 4.3% in the fourth quarter compared to the same period last year and amounted to SEK 3,435 million (3,293). Organic growth amounted to 0.9% and the rest of the increase represents positive currency effects. The operating profit for the quarter amounted to SEK 256 million (229), an increase of 11.8% compared with the same period last year. The operating margin amounted to 7.4% (6.9%). Net profit totalled SEK 183 million (164). Profit per share amounted to SEK 1.42 (1.28). The company's cash

All patients enrolled for ChloraSolv01

RLS Global is pleased to announce that all patients are included in the study ChloraSolv 01, which has been performed on nine sites in Sweden. The inclusion criteria for the study are chronic wounds below the knee. The aim with the study is to obtain clinical data to regulatory extend the indication for use (diabetic foot ulcers) to all types of chronical wounds below the knee (venous leg ulcers, arterial/mix wounds etc.). ChloraSolv01 is a pilot study. The patients are treated with ChloraSolv for six weeks with six weeks follow up. We are measuring, among other things, the differences of

The Phase 1/2a study ISO-CC-005 is completed

GOTHENBURG, Sweden, January 30, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announces that the recruitment and treatment of patients in the company's Phase 1/2a study with arfolitixorin has been completed. Totally 101 patients have been treated at 10 hospitals in the Nordic countries and Europe. The final analysis has started and study data is expected to be presented at ESMO 2020.Ulf Jungnelius, M.D., Chief Executive Officer of Isofol, comments: “ISO-CC-005 has fulfilled its purpose by determining the dose we have chosen for further development in our Global

Attendo's year-end report for 2019 to be published on 13 February - Invitation to teleconference

On 13 February, around 08:00 am (CET), Attendo will present its year-end report and fourth quarter results for 2019. Investors, analysts and journalists are hereby invited to participate in a teleconference at 10:00 am (CET) on the same date.The teleconference will be hosted by Attendo’s CEO Martin Tivéus and CFO Fredrik Lagercrantz. The presentation will be held in English. Date:             13 February 2020Time:             10:00 am (CET) To participate in the conference, please dial in on any number below at least ten minutes before the start of the call: SE:

There are no items matching the current filter
There are no more items matching the current filter
Back to top